Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
$31.66
$8.62
$58.94
$73.49M2.1532,471 shs77 shs
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$0.64
C$0.64
C$0.38
C$8.17
C$90.27MN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$0.26
-3.8%
C$0.26
C$0.15
C$0.53
C$52.28MN/A644,760 shs384,329 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.16
+2.7%
$1.14
$0.57
$2.58
$194.81M0.492.31 million shs11.04 million shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
0.00%0.00%0.00%0.00%0.00%
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.00%0.00%0.00%0.00%0.00%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00%0.00%0.00%0.00%0.00%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-12.40%-5.83%-22.07%+45.84%-24.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
N/AN/AN/AN/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.6674 of 5 stars
3.32.00.04.60.62.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
3.00
Buy$3,400.00∞ Upside
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.50
Moderate Buy$3.00158.62% Upside

Current Analyst Ratings

Latest CSU, MDG1, EMH, CTST, and XFOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
$383.86M0.00N/AN/A($131.19) per share0.00
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$35.22M2.56N/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/A$0.31 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
-$295.37M$49.780.67N/AN/A40.40%N/A-5.64%N/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
-C$10.46MN/A0.00N/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A-C$0.70N/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$101.17M-$0.60N/AN/AN/AN/A-170.10%-65.44%5/2/2024 (Estimated)

Latest CSU, MDG1, EMH, CTST, and XFOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$0.15-$0.10+$0.05-$0.10N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
N/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
N/A
0.11
0.11
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
35.45
2.97
2.61
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
1.07
5.34
5.34

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
62.65%
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.03%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Capital Senior Living Co. stock logo
CSU
Capital Senior Living
3,4162.19 million2.07 millionOptionable
CannTrust Holdings Inc stock logo
CTST
CannTrust
576141.49 millionN/AOptionable
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
161205.03 millionN/ANot Optionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
93167.94 million166.12 millionOptionable

CSU, MDG1, EMH, CTST, and XFOR Headlines

SourceHeadline
Head to Head Survey: X4 Pharmaceuticals (NASDAQ:XFOR) vs. OKYO Pharma (NASDAQ:OKYO)Head to Head Survey: X4 Pharmaceuticals (NASDAQ:XFOR) vs. OKYO Pharma (NASDAQ:OKYO)
americanbankingnews.com - April 26 at 1:56 AM
X4 Pharmaceuticals: PDUFA Excitement AheadX4 Pharmaceuticals: PDUFA Excitement Ahead
seekingalpha.com - April 18 at 12:45 AM
X4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62X4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62
msn.com - April 17 at 7:45 PM
X4 Pharmaceuticals, Inc.s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returnsX4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
finance.yahoo.com - April 11 at 1:43 PM
Research Analysts Issue Forecasts for X4 Pharmaceuticals, Inc.s Q1 2024 Earnings (NASDAQ:XFOR)Research Analysts Issue Forecasts for X4 Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:XFOR)
marketbeat.com - April 5 at 8:05 AM
Brokers Set Expectations for X4 Pharmaceuticals, Inc.s Q2 2024 Earnings (NASDAQ:XFOR)Brokers Set Expectations for X4 Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:XFOR)
marketbeat.com - April 4 at 8:48 AM
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - April 2 at 4:05 PM
XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…
finance.yahoo.com - April 2 at 10:26 AM
X4 Pharmaceuticals to Participate in Upcoming April Investor ConferencesX4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
globenewswire.com - April 1 at 8:00 AM
X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call TranscriptX4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 23 at 3:45 PM
Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor ProspectsBuy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects
markets.businessinsider.com - March 22 at 5:16 PM
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call TranscriptX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript
insidermonkey.com - March 22 at 3:06 PM
Q4 2023 X4 Pharmaceuticals Inc Earnings CallQ4 2023 X4 Pharmaceuticals Inc Earnings Call
finance.yahoo.com - March 22 at 2:14 AM
XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023
investorplace.com - March 21 at 12:09 PM
X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial ResultsX4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results
finance.yahoo.com - March 21 at 10:08 AM
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateX4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
globenewswire.com - March 21 at 6:01 AM
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
globenewswire.com - March 12 at 8:00 AM
Arthur Taveras Sells 14,235 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) StockArthur Taveras Sells 14,235 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock
insidertrades.com - March 12 at 5:38 AM
XFOR Jan 2026 1.000 callXFOR Jan 2026 1.000 call
finance.yahoo.com - March 9 at 7:38 AM
XFOR Apr 2024 1.500 callXFOR Apr 2024 1.500 call
finance.yahoo.com - March 9 at 7:38 AM
X4 Pharmaceuticals Inc (XFOR)X4 Pharmaceuticals Inc (XFOR)
investing.com - March 2 at 3:21 AM
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 1 at 4:05 PM
X4 Pharmaceuticals Stock (NASDAQ:XFOR), Short Interest ReportX4 Pharmaceuticals Stock (NASDAQ:XFOR), Short Interest Report
benzinga.com - February 24 at 12:32 AM
XFOR Mar 2024 1.500 putXFOR Mar 2024 1.500 put
finance.yahoo.com - February 23 at 9:28 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Capital Senior Living logo

Capital Senior Living

NYSE:CSU
Capital Senior Living Corp. engages in the operation of senior housing communities. Its senior living options include independent living, assisted living, and memory care. The company was founded in 1990 and is headquartered in Dallas, TX.
CannTrust logo

CannTrust

NYSE:CTST
CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.
Emerald Health Therapeutics logo

Emerald Health Therapeutics

CVE:EMH
Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.
X4 Pharmaceuticals logo

X4 Pharmaceuticals

NASDAQ:XFOR
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.